Compare Nu Holdings Ltd (NU) vs Novartis AG (NVS) Price & Performance

NU Holdings stock trades at $15.33, down slightly by 0.26% today, with a bullish technical signal from moving averages and a consensus analyst price target of $17.20. The company reported strong Q2 2026 results, including a 39% revenue growth and record net income exceeding $1 billion, driven by expanding customer base and AI integration. Cash flow from operations reached $3.5 billion in 2025, supporting robust financial health.

Outlook remains positive with growth opportunities in Mexico and AI-driven efficiencies, but risks include credit quality concerns and competitive pressures. Analysts are predominantly bullish, with 57% recommending buy, though investors should monitor debt levels and macroeconomic factors affecting fintech sectors.

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.